Cyclophosphamide in systemic sclerosis: Light and shadows

Clinical and Experimental Rheumatology

Volumn 22, Issue 5, 2004, Pages 551-552

  Vlachoyiannopoulos, Panayiotis G ^a,b   Ioannidis, John P A ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISOLONE;

CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESEARCH; DRUG USE; EDITORIAL; FIBROSING ALVEOLITIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC;

EID: 4644230917     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. VLACHOYIANNOPOULOS PG, DAFNI UG, PAKAS I, SPYROPOULOU-VLACHOU M, STAVROPOULOS-GIOKAS C, MOUTSOPOULOS HM: Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000; 59: 359-67.
2. FERRI C, VALENTINI G, COZZI F et al.: Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
3. de CLERCK LS, DEQUEKER J, FRANCX L, DEMEDTS M: D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term followup study. Arthritis Rheum 1987; 30: 643-50.
4. VLACHOYIANNOPOULOS PG, TSIFETAKI N, DIMITRIOU I, GALARIS D, PAPIRIS SA, MOUTSOPOULOS HM: Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis 1996; 55: 761-8.
5. SILVER RM, MILLER KS, KINSELLA MB, SMITH EA, SCHABEL SI: Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990; 88: 470-6.
6. IOANNIDIS JP, KARASSA FB: Bias in uncontrolled therapeutic trials in rheumatology due to selection of populations with extreme characteristics. J Rheumatol 2001; 28: 1881-7.
7. KYRIAKIDI M, IOANNIDIS JP: Design and quality considerations for randomized controlled trials in systemic sclerosis. Arthritis Rheum 2002; 47: 73-81.
8. MATUCCI-CERINIC M, D'ANGELO S, DENTON CP, VLACHOYIANNOPOULOS PG, SILVER S: Assessment of lung involvement. Clin Exp Rheumatol 2003; 21 (Suppl. 29): S19-S23.
9. AIRO P, DANIELI E, PARRINELLO G et al.: Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol 2004; 22: 573-8.
10. VARAI G, EARLE L, JIMENEZ SA, STEINER RM, VARGA J: A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325-9.
11. DAVAS EM, PEPPAS C, MARAGOU M, ALVANOU E, HONDROS D, DANTIS PC: Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18: 455-61.
12. PAKAS I, IOANNIDIS JP, MALAGARI K, SKOPOULI FN, MOUTSOPOULOS HM, VLACHOYIANNOPOULOS PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
13. GRIFFITHS B, MILES S, MOSS H, ROBERTSON R, VEALE D, EMERY P: Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-8.
14. GIACOMELLI R, VALENTINI G, SALSANO F et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
15. LATSI PI, WELLS AU: Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003; 15: 748-55.
16. BOUROS D, WELLS AU, NICHOLSON AG et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-6.
17. KIM DS, YOO B, LEE JS et al.: The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 121-7.
18. MacDONALD SL, RUBENS MB, HANSELL DM et al.: Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001; 221: 600-5.
19. WHITE B, BAUER EA, GOLDSMITH LA et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995; 38: 351-60.
20. WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.